BOSTON, Aug. 11 (UPI) -- People who already have colorectal cancer and use aspirin regularly had a lower risk of cancer death than those not taking aspirin, U.S. researchers say.
Dr. Andrew T. Chan of Massachusetts General Hospital and Harvard Medical School in Boston and colleagues studied the association between aspirin use and survival among 1,279 men and women with non-metastatic -- stage I, II, and III -- colorectal cancer who were participating in two large studies.
The study, published in the Journal of the American Medical Association, finds regular use of aspirin after diagnosis was associated with a significant reduction in risk of colorectal cancer-specific death and a reduction in overall mortality. Compared with non-users, regular aspirin use after diagnosis was associated with a 29 percent lower risk for colorectal-specific mortality and a 21 percent lower risk for overall mortality.
However, among the 719 participants who did not use aspirin before diagnosis, initiation of use post-diagnosis was associated with a 47 percent lower risk for colorectal cancer-specific mortality and a 32 percent lower risk of overall mortality. In contrast, among participants who were using aspirin before diagnosis, continuation of aspirin use post-diagnosis was not associated with a significant reduction in colorectal cancer-specific survival or overall survival.